Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 2.10M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
11: R1 Cover Page HTML 74K
12: R2 Condensed Consolidated Statements of Income HTML 101K
(Unaudited)
13: R3 Condensed Consolidated Statements of Comprehensive HTML 55K
Income (Unaudited)
14: R4 Condensed Consolidated Statements of Comprehensive HTML 34K
Income (Unaudited) (Parenthetical)
15: R5 Condensed Consolidated Balance Sheets (Unaudited) HTML 154K
16: R6 Condensed Consolidated Balance Sheets (Unaudited) HTML 39K
(Parenthetical)
17: R7 Condensed Consolidated Statements of Cash Flows HTML 92K
(Unaudited)
18: R8 Basis of Presentation and Summary of Significant HTML 27K
Accounting Policies
19: R9 New Accounting Standards HTML 35K
20: R10 Revenue HTML 63K
21: R11 Net Income Per Share HTML 37K
22: R12 Inventories HTML 29K
23: R13 Leases HTML 59K
24: R14 Affiliated Companies HTML 27K
25: R15 Debt HTML 45K
26: R16 Derivative Financial Instruments HTML 134K
27: R17 Fair Value Measurements HTML 82K
28: R18 Accumulated Other Comprehensive Loss HTML 101K
29: R19 Shareholders' Equity HTML 145K
30: R20 Stock-Based Compensation HTML 28K
31: R21 Benefit Plans HTML 116K
32: R22 Other (Income) Expense HTML 52K
33: R23 Income Taxes HTML 26K
34: R24 Commitments and Contingencies HTML 25K
35: R25 Segment Information HTML 76K
36: R26 Basis of Presentation and Summary of Significant HTML 30K
Accounting Policies (Policies)
37: R27 Revenue (Tables) HTML 59K
38: R28 Net Income Per Share (Tables) HTML 35K
39: R29 Inventories (Tables) HTML 30K
40: R30 Leases (Tables) HTML 62K
41: R31 Debt (Tables) HTML 35K
42: R32 Derivative Financial Instruments (Tables) HTML 136K
43: R33 Fair Value Measurements (Tables) HTML 75K
44: R34 Accumulated Other Comprehensive Loss (Tables) HTML 102K
45: R35 Shareholders' Equity (Tables) HTML 141K
46: R36 Benefit Plans (Tables) HTML 105K
47: R37 Other (Income) Expense (Tables) HTML 51K
48: R38 Segment Information (Tables) HTML 70K
49: R39 Revenue - Revenue Recognition (Details) HTML 58K
50: R40 Revenue - Contracts and Liabilities (Details) HTML 33K
51: R41 Revenue - Narrative (Details) HTML 34K
52: R42 Net Income Per Share - Summary of Net Income Per HTML 43K
Share (Details)
53: R43 Net Income Per Share - Narrative (Details) HTML 34K
54: R44 Inventories (Details) HTML 31K
55: R45 Leases - Lease Cost (Details) HTML 31K
56: R46 Leases - Lease Cash Flow and Supplemental HTML 27K
Information (Details)
57: R47 Leases - Lease Weighted Average (Details) HTML 26K
58: R48 Leases - Maturities of Operating Lease Liabilities HTML 45K
(Details)
59: R49 Affiliated Companies (Details) HTML 37K
60: R50 Debt - Long-term Debt (Details) HTML 46K
61: R51 Debt - Narrative (Details) HTML 90K
62: R52 Derivative Financial Instruments - Foreign HTML 68K
Exchange Rate and Commodity Price Risk (Details)
63: R53 Derivative Financial Instruments - Effects of HTML 85K
Derivative Instruments on OCI and Earnings
(Details)
64: R54 Fair Value Measurements - Assets and Liabilities HTML 64K
Recorded at Fair Value (Details)
65: R55 Fair Value Measurement - Other Financial HTML 25K
Instruments (Details)
66: R56 Accumulated Other Comprehensive Loss - Components HTML 59K
of Accumulated Other Comprehensive Income
(Details)
67: R57 Accumulated Other Comprehensive Loss - Other HTML 88K
Comprehensive Loss Reclassifications (Details)
68: R58 Shareholder's Equity - Change in Shareholders' HTML 83K
Equity (Details)
69: R59 Shareholder's Equity - Supplemental Equity HTML 23K
Information (Details)
70: R60 Stock-Based Compensation (Details) HTML 58K
71: R61 Benefit Plans - Schedule of Components of Net HTML 64K
Periodic Benefit Cost (Details)
72: R62 Benefit Plans - Narrative (Details) HTML 27K
73: R63 Other (Income) Expense - Summary (Details) HTML 36K
74: R64 Other (Income) Expense - Narrative (Details) HTML 36K
75: R65 Other (Income) Expense - Restructuring and Related HTML 40K
Charges (Details)
76: R66 Other (Income) Expense - Other Items (Details) HTML 35K
77: R67 Income Taxes (Details) HTML 28K
78: R68 Segment Information (Details) HTML 66K
81: XML IDEA XML File -- Filing Summary XML 147K
79: XML XBRL Instance -- wst-20220630_htm XML 3.06M
80: EXCEL IDEA Workbook of Financial Reports XLSX 138K
7: EX-101.CAL XBRL Calculations -- wst-20220630_cal XML 203K
8: EX-101.DEF XBRL Definitions -- wst-20220630_def XML 475K
9: EX-101.LAB XBRL Labels -- wst-20220630_lab XML 1.46M
10: EX-101.PRE XBRL Presentations -- wst-20220630_pre XML 850K
6: EX-101.SCH XBRL Schema -- wst-20220630 XSD 137K
82: JSON XBRL Instance as JSON Data -- MetaLinks 423± 620K
83: ZIP XBRL Zipped Folder -- 0000105770-22-000047-xbrl Zip 389K
In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the
date hereof (the “Report”), I, Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
